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Roles of defective apoptosis in malignancy
Each day, the average adult produces and in parallel eradicates 50 ± 70 billion cells in the body, making way for a commensurate number of new cells which are produced daily through cell division, and thereby ensuring tissue homeostasis. This cell eradication occurs largely through programmed cell death, and involves a constellation of morphological changes known as`apoptosis' (Wyllie, 1997b) . Dysregulation of programmed cell death occurs commonly in hematological and other types of malignancies, promoting cell accumulation by slowing the rate of cell turnover and endowing neoplastic clones with a selective survival advantage relative to their normal counterparts. Defects in normal apoptosis mechanisms also contribute in multiple ways to tumor progression (for reviews, see Reed, 1999a; Wyllie, 1997a) . Indeed, apoptosis defects create a permissive soil on which the seeds of oncogene activation, genetic instability, and metastasis can take root and thrive. For example, many oncogenes (C-MYC; CYCLIN-D1 (BCL-1); E1a) that drive the cell cycle also induce pathways for apoptosis, providing an intrinsic check against tumorigenesis. Defects in apoptosis mechanisms permit survival of cells that harbor activated oncogenes (Evan and Littlewood, 1998) . Similarly, defects in DNA repair and chromosome segregation normally trigger cell suicide as a defense mechanism for eradicating genetically unstable cells. Apoptosis-defects permit the survival of the genetically unstable cells, and thus provide opportunities of selection of progressively aggressive clones (Anthoney et al., 1996) . Likewise, at least for epithelial malignancies, most cancer cells have exceedingly low survival rates in the circulation (reviewed in Frisch and Ruoslahti, 1997) . However, metastatic cancer cells survive in a non-adherent state, escape to target organs, and form distant tumors. Thus, a critical attribute of the metastatic cell is its acquired ability to survive in a non-adherent state. Apoptosis defects also play roles in tumor resistance to hypoxia, growth factor deprivation, immune surveillance mechanisms, chemotherapy, radiation, and other selective pressures (Graeber et al., 1996; Makin and Hickmann, 2000; Medh and Thompson, 2000; Rinkenberger and Korsmeyer, 1997; Strasser et al., 1997) . Thus, understanding normal apoptosis mechanisms is critical for developing a better base of knowledge from which to undertake strategies for improved treatment of cancer.
Apoptosis pathways and apoptosis genes
Apoptosis is caused by proteases known as`caspases' for Cysteine Aspartyl-speci®c Proteases (Cryns and Yuan, 1999; Thornberry and Lazebnik, 1998) . Caspases constitute a family of intracellular cysteine proteases, which cleave substrates at aspartic acid (Asp) residues. Produced initially as inactive zymogens, Caspases are triggered into activation generally as a result of their proteolytic processing at conserved Asp residues within the polypeptide pro-protein. Because Caspases cleave their substrates at Asp residues and are also activated by proteolytic processing at Asp residues, these proteases can collaborate in proteolytic cascades, where Caspases activate themselves and each other (Karanewsky et al., 1998; Thornberry et al., 1997) . Within these proteolytic cascades, Caspases can be positioned as either upstream`initiators' or downstream`eectors' of apoptosis (Salvesen and . The proforms of upstream initiator Caspases possess large N-terminal pro-domains, which function as protein interaction modules, allowing them to associate with various proteins that trigger Caspase activation. In contrast, downstream eector Caspases contain only short N-terminal prodomains, and are largely dependent on upstream Caspases for their proteolytic processing and activation. The preferred tetrapeptide sequences recognized by upstream Caspases are commonly found within the downstream Caspase zymogens at the Asp cleavage sites, further contributing to a hierarchy of proteolytic events, but the relationships among the various Caspases within protease cascades can be somewhat tissue-and stimulus-speci®c (Tang et al., 2000; Zheng et al., 2000) , making it dicult to map a uniform sequence of proteolytic events analogous to the coagulation or complement cascades. Eleven caspases have been identi®ed in the human genome (http://apoptosisdb.org).
Several pathways for activating Caspases probably exist, though details remain sketchy for some of them (Figure 1 ). The simplest is exploited by Cytolytic Tcells (CTL) and Natural Killer (NK) cells, which inject apoptosis-inducing proteases, particularly Granzyme B, into target cells via perforin channels (reviewed in Lowin et al., 1995) . Unlike the Caspases, Granzyme B is a serine protease, but similar to the Caspases, Granzyme B speci®cally cleaves substrates at Asp residues. Granzyme B is capable of cleaving and activating multiple Caspases and some Caspase substrates. An endogenous inhibitor of Granzyme B, a 19 kDa serpin, has been identi®ed which is expressed in CTLs, NK cells, dendritic cells and certain other tissues (Bladergroen et al., 2001) . Some viruses also produce inhibitors of Granzyme B, such as the CrmA protein of cowpox virus , thereby avoiding (or at least delaying) immune cell destruction of virusinfected cells and thus allowing sucient time for viral replication. Accordingly, the kinetics of killing of virusinfected cells by CTLs derived from granzyme B knock-out mice is delayed, but not ablated. Allogenic recipients of bone marrow from granzyme B knock-out mice have reduced Graft-Versus-Host Disease (GVHD), consistent with a role for this protease in CTL-mediated killing (Graubert et al., 1997) , and implying that pharmacological inhibitors of GraB might be applied for this condition.
Another Caspase-activation pathway is represented by Tumor Necrosis Factor (TNF)-family receptors. Eight of the *30 known members of the TNF family in humans contain a so-called Death Domain (DD) in their cytosolic tails (Locksley et al., 2001) . Several of these DD-containing TNF-family receptors use Caspase-activation as a signaling mechanism, including TNFR1/CD120a; Fas/APO1/CD95; DR3/Apo2/ Weasle; DR4/TrailR1; DR5/TrailR2; and DR6. Ligation of these receptors at the cell surface results in the recruitment of several intracellular proteins, including certain pro-Caspases, to the cytosolic domains of these receptors, forming a`death-inducing signaling complex' (DISC) that triggers Caspase activation and leads to apoptosis (reviewed in Wallach et al., 1999; Yuan, 1997) . The speci®c Caspases recruited to the DISC are pro-Caspase-8 and (in humans) pro-Caspase-10. These Caspases contain Death Eector Domains (DEDs) in their N-terminal prodomains that bind a corresponding DED in the adapter protein, FADD, thus linking them to the TNF-family Death Receptor complexes. Cells derived from caspase-8 knock-out mice fail to undergo apoptosis in response to ligands or antibodies that activate TNF-family death receptors, demonstrating an essential role for this Caspase in this pathway (Juo et al., 1998; Varfolomeev et al., 1998) . However, in contrast to Caspase-8, mice may lack the highly homologous protease, Caspase-10, which is found in humans, having arisen from an apparent gene duplication on chromosome 2q33 (Takita et al., 2001) . Thus, it is unclear whether Caspases-8 and 10 display at least some redundancy in human tissues.
Mitochondria also play important roles in apoptosis induction, releasing Cytochrome-c (Cyt-c) into the cytosol, which then causes assembly of a multiprotein Caspase-activating complex, referred to as the`apoptosome' (reviewed in Green and Reed, 1998; Reed, 1997) . The central component of the apoptosome is Apaf1, a Caspase-activating protein that oligomerizes upon binding Cytochrome c and which speci®cally binds pro-Caspase-9. Apaf1 and pro-Caspase-9 interact with each other via their Caspase-Associated Recruitment Domains (CARDs). Such CARD-CARD interactions play important roles in many steps in apoptosis pathways. Cells from caspase-9 knock-out mice are completely defective in apoptosis induction via the mitochondrial pathway, demonstrating the essential nature of this particular Caspase for Cytochrome cinduced apoptosis (Hakem et al., 1998; Kuida et al., 1998) . The mitochondrial pathway for apoptosis is activated by myriad stimuli, including oxidants, Ca 2+ over-load, DNA-damaging agents, growth factor deprivation and other insults. Mitochondria can also participate in cell death pathways induced via TNFfamily death receptors, through cross-talk mechanisms involving proteins such as Bid (Li et al., 1998a; Luo et al., 1998) BAR , and Bap31 (Ng et al., 1997) . However, mitochondrial (`intrinsic') and death receptor (`extrinsic') pathways for Caspase activation are fully capable of independent operation in most types of cells (Vaux and Strasser, 1996) . In addition to Cytochrome c, mitochondria also release several other proteins of relevance to apoptosis, including Endonuclease G, AIF (Joza et al., 2001) (an activator of nuclear endonucleases), and IAPantagonists Smac (Diablo) Li et al., 2001; Parrish et al., 2001; Susin et al., 1999; Suzuki et al., 2001; Verhagen et al., 2000) .
A Caspase activation pathway linked to endoplasmic reticulum (ER)/Golgi stress has been proposed. Caspase-12 may represent the apical protease linked to this pathway in mice (Nakagawa et al., 2000) . However, humans lack a clear orthologue of A connection between Caspase-2 and the Golgi has also been suggested but details are unclear (Mancini et al., 2000) . Both Caspase-2 and -12 are CARD-carrying proteins, which engage other apoptosis-regulators such as Raidd (Cradd) via homotypic interactions among CARD domains. A pro-Caspase-12-binding complex of IRE and TRAF2 has also described (Yoneda et al., 2001) .
Finally, a nuclear pathway for apoptosis regulation may exist which centers on discrete nuclear organelles, called Pml Oncogenic Domains (PODs) or Nuclear Bodies (NBs) (reviewed in Hess and Korsmeyer, 1998) . Targeted ablation of the pml gene in mice results in general resistance to apoptosis, through an unknown mechanism (Wang et al., 1998b) . Several proteins that can promote or induce apoptosis have been localized to PODs, including Daax, Zip Kinase, and Par4. How these nuclear structures are linked to Caspase activation pathways is unknown.
Multiple antagonists of these Caspase-activation pathways have been discovered and examples of dysregulation of their expression or function in cancers have been obtained. Since our knowledge is deepest so far where the mitochondrial (`intrinsic') and TNFfamily Death Receptor (`extrinsic') pathways for apoptosis are concerned, most of our information about antagonists centers on these two apoptotic pathways ( Figure 2 ). For example, antagonists of the Intrinsic Pathway include: (i) anti-apoptotic Bcl-2 family proteins which prevent mitochondrial release of Cytochrome c and other apoptogenic proteins from these organelles (Green and Reed, 1998; ; (ii) the kinase Akt (PKB), which can phosphorylate and inactivate the Bcl-2 antagonist protein BAD and the protease Caspase-9 (Datta et al., 1999) ; (iii) TUCAN, a CARD-protein that binds and sequesters pro-Caspase-9 (Pathan et al., 2001) ; and (iv) IAPfamily apoptosis-suppressors, which bind and directly inhibit Caspases-3, -7, and -9 (Deveraux and Reed, 1999) . Likewise, multiple antagonists of the Extrinsic Pathway have been identi®ed, including several DEDcontaining proteins that compete for binding to the adapter proteins or pro-Caspases that participate in TNF-family death receptor signaling, including FLIP, BAR, and possibly Bap31 (reviewed in Krammer, 2000; Tschopp et al., 1999) . The IAPs also suppress this pathway by binding and inhibiting downstream eector Caspases (Figure 2) . In yet another level of regulation, IAP-antagonists have been revealed, including Smac (Diablo) and HtrA2 (Omi) in mammals. These proteins are normally sequestered in mitochondria. When released, they bind IAPs, freeing the Caspases to do their job as eectors of apoptosis (Chai et al., 2000; Du et al., 2000; Srinivasula et al., 2001; Suzuki et al., 2001; Verhagen et al., 2000) .
Altogether, at least 104 human genes have been identi®ed which contain one or more of the signature domains typically associated with participation in apoptosis pathways, including 11 with caspase protease domains, 22 with CARDs, 28 Death Domain (DD) proteins, 11 DEDs, eight with the BIR domain found in IAPs, and 24 Bcl-2-family members (Table 1) . We consider these 104 genes to be the`core' components of the human cell death pathway. This list however does not include several other proteins that may provide inputs into the core pathway, such as protein kinases (e.g. Akt; IKK) and transcription factors (e.g. nuclear receptors such as PPARg; RXR; TR3; AR; GR and p53-family members including p53, p63, and p73), which have been implicated in apoptosis control. Nor does the list in Table 1 include regulators one-step removed from the core machinery such as IAPantagonists (e.g. Smac; Omi; XAF), TNF-family Receptor antagonists (e.g. DcR1; DcR2; DcR3), and BAG-family proteins such as BAG1, 3, 4, and 6 which are known to interact with core-pathway proteins and which contain a conserved Hsp70-binding domain that allows them to target this molecular chaperone upon apoptosis-relevant proteins so that their functions can be altered through conformational changes in protein structure (reviewed in Takayama and Reed, 2001) . Mitochondrial proteins that could modulate apoptosis sensitivity due to their reported interactions with Bcl-2 family proteins, or their putative roles as downstream eectors of the mitochondrial cell death pathway, are also not present on the list (e.g. Adenine Nucleotide Translocation (ANT); Voltage Dependent Anion Channel (VDAC); Peripheral Benzodiazapine Receptor (PBR); Cytochrome c; AIF; Cyclophilin-D). Thus, in addition to these core components of the cell death machinery, numerous upstream and downstream modulators of apoptosis probably exist in the human genome. Moreover, the relevance of many other genes to apoptosis regulation is probably unrecognized at present, awaiting strategies that can reveal their impact.
Apoptosis and hematological malignancies
Much of our knowledge of apoptosis mechanisms has come from studies of malignancies of hematopoietic and lymphoid origin. For example, the ®rst antiapoptotic gene identi®ed was BCL2, which was discovered because of its involvement in the t(14;18) chromosomal translocations commonly associated with non-Hodgkin's B-cell lymphomas (Tsujimoto and Croce, 1986) . Studies of Bcl-2 led to an appreciation of the important role of mitochondria in apoptosis (Hockenbery et al., 1990; Newmeyer et al., 1994) , and laid the foundation for discovery of the other Bcl-2 family members in humans and multiple other species. Another example of the in¯uence that studies of hematopoietic and lymphoid malignancies have had on apoptosis research is found in Fas (CD95), a member of the TNF-family of death receptors. Mice and humans with hereditary mutations in either Fas (lpr/lpr) or its ligand (gld/gld) develop a lymphoproliferative syndrome with associated autoimmunity (Takahashi et al., 1994; Watanabe-Fukunaga et al., 1992) . Studies of Fas provided the ®rst example of a receptor-mediated signal transduction mechanism that results in protease activation, a milestone in cell biology research, and revealed that pathways exist for purposeful triggering of cell suicide (Itoh et al., 1991; Oehm et al., 1992) . Early indications of the involvement of proteases in apoptosis came from studies of the actions of DNA-damaging anticancer drugs on leukemia cell lines, demonstrating proteolysis of Poly-ADP Ribosyl Polymerase (PARP) (Kaufmann et al., 1991) , which was later determined to be a prominent substrate of eector Caspases.
In this review, we summarize some of the recent observations regarding dysregulation of apoptosis mechanisms in hematopoietic and lymphoid malignancies. Emphasis has been placed on core apoptosis components such as Bcl-2, Caspase, and IAP family proteins, focusing on instances where structural 104 genes within CORE apoptotic machinery of humans (~0.25% of human genome, based on ~40 000 estimate) (Table 2 ). For purposes of brevity, we have largely ignored abundant data implicating epigenetic mechanisms and changes in extracellular stimuli (growth factors, adhesion proteins, etc.), which undoubtedly also make important contributions to the altered expression of apoptosis-regulatory genes in hematopoietic malignancies. Examples of genetic alterations aecting molecules that provide important regulatory inputs into the cell death machinery are also described.
Core components of the apoptosis machinery
BCL-2
The BCL-2 gene at 18q21 is involved in chromosomal translocations with the immunoglobulin heavy-chain (IgH) locus at 14q32 in over half of all non-Hodgkin's Lymphomas (NHLs), including *90% of follicular Bcell lymphomas and *one-third of diuse large cell lymphomas (Weiss et al., 1987) . This chromosomal translocation event places the BCL-2 gene into juxtaposition with powerful enhancer elements associated with the IgH locus, causing transcriptional deregulation of the BCL-2 gene and resulting in elevated levels of BCL-2 mRNA and Bcl-2 protein production. Because of the somatic hypermutation mechanism associated with the IgH locus, which normally participates in V h gene diversi®cation, the translocated BCL-2 allele can accumulate somatic point mutations. These mutations may either contribute to deregulation of BCL-2 gene expression or endow the Bcl-2 protein with enhanced functions. For example, mutations eecting Aspartic Acid 34 of the Bcl-2 protein have been demonstrated in translocated BCL-2 alleles (Tanaka et al., 1992) , thus ablating a Caspase cleavage site that has the potential to convert Bcl-2 from a cytoprotective to a pro-apoptotic protein (Cheng et al., 1997) . Mutations in a proline-rich`loop' region of Bcl-2 that somehow autorepresses its function have also been described in NHLs (Chang et al., 1997; Reed and Tanaka, 1993) . Aside from chromosomal translocations, BCL-2 gene ampli®cation has also been described in 11 ± 23% of diuse large B-cell lymphomas (Rao et al., 1998) . Over-expression of Bcl-2 protein in the absence of demonstrable alterations in the structure or copy-number of the gene also commonly occurs, and has been associated with poor prognosis in intermediate grade NHLs (Gascoyne et al., 1997; Hermine et al., 1996; Hill et al., 1996) . Translocations involving BCL-2 represent a very early event in the pathogenesis of B-cell NHLs, and are associated with additional chromosomal alterations as these malignancies undergo progression. In this regard, a classical example of oncogene complementation is found in t(14;18)-bearing B-cell lymphomas that develop secondary translocations involving the C-MYC gene ± such as the t(8:14) translocation that places C-MYC into juxtaposition with the IgH locus (Gauwerky et al., 1988) . The protein encoded by C-MYC drives cell division, but also stimulates apoptosis. Over-expression of BCL-2 counteracts the pro-apoptotic eects of C-MYC, leaving its proliferative functions intact (reviewed in Evan and Littlewood, 1998). Consequently, lymphomas in which both BCL-2 and C-MYC have become activated are extremely aggressive.
Elevations in Bcl-2 protein without concomitant structural alterations in the BCL-2 gene are commonly found in a variety of hematopoietic malignancies, including Multiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL), Acute Lymphocytic Leukemia (ALL), and Acute Myelogenous Leukemia (AML). Several studies have suggested that elevated levels of Bcl-2 protein expression may be associated with adverse clinical outcome (reduced rates of complete remission, shorter disease-free or overall survival) for some groups of patients with CLL, AML, and other hematopoietic malignancies (see for example references Campos et al., 1993; Pepper et al., 1996 Pepper et al., , 1998b . The explanation for the high levels of Bcl-2 protein production observed in these cases is unclear, but altered expression or function of transcription factors that control the BCL-2 gene promoter may be involved in some circumstances. For instance, the WT-1 gene encodes a zinc-®nger DNA-binding protein that functions as a transcription factor for multiple target genes. The WT-1 protein directly interacts with the BCL-2 gene promoter, increasing its expression (Hewitt et al., 1995; Mayo et al., 1999) . Approximately threequarters of AMLs contain WT-1 and high levels of this transcription factor are associated with decreased overall survival (Bergmann et al., 1997) . In another example, the t(8;21) chromosomal translocation seen in AML (Fab class, M2) places the AML1 gene into juxtaposition with the ETO gene. In vitro, the AML1/ ETO fusion protein binds the BCL-2 promoter and increases transcription of this survival factor (Klampfer et al., 1996) . Because two studies have reported that patients with t(8;21) have low levels of Bcl-2 protein (Banker et al., 1998; Shikami et al., 1999) however, the correlation of Bcl-2 and AML1/ETO in primary leukemic cells requires further clari®cation.
In addition to Bcl-2, examples of over-expression of closely related anti-apoptotic members of the Bcl-2 family have also been found in hematological malignancies. For example, elevations in Mcl-1 have been reported in acute leukemias after relapse from chemotherapy, where matched pairs of specimens from pre-and post-treatment patients were compared (Kaufmann et al., 1998) . Higher levels of Mcl-1 have also been associated with failure to achieve complete remission (CR) in B-CLL (Kitada et al., 1998) . The mechanisms responsible for altered Mcl-1 expression are unknown.
Similarly, evidence of increased expression of the anti-apoptotic protein Bcl-X L has been found in some types of hematopoietic malignanies, including CML and MM. Nearly all CMLs harbor a Philadelphia chromosome, which fuses portions of the C-ABL proto-oncogene at 9q34 with the BCR gene locus at 22q11, thereby generating oncogenic BCR-ABL fusion proteins (Heisterkamp et al., 1985) . The BCR-ABL protein displays constitutively active protein tyrosine kinase activity, triggering a number of down-stream signal-transduction pathways, including activation of STAT5 in CMLs. The STAT5 protein directly binds the promoter of the BCL-X gene, inducing its transcription (de Groot et al., 2000; Gesbert, 2000) . In MM, an autocrine loop involving IL-6 production and IL-6 receptor engagement has been shown to result in STAT activation and increased BCL-X gene expression (Dalton and Jove, 1999) . More examples of transcriptional deregulation of structurally intact (wild-type) BCL-2 family genes are likely to emerge as research continues.
BAX
The cytoprotective function of Bcl-2 can be attributed at least in part to the ability of this protein to oppose apoptosis induction by Bax, a pro-apoptotic member of the Bcl-2 family (Gross et al., 1999) . Gene knockout studies in mice, as well as human tumor xenograft studies, have provided evidence that BAX can function as a tumor suppressor gene (Yin et al., 1997) . Mutations that inactivate the BAX gene have been observed in both solid tumors and hematopoietic malignancies (Brimmell et al., 1998; Rampino et al., 1997) . Though the frequency of such mutations may be relatively rare, BAX gene mutations have been detected in T-cell acute lymphocytic leukemias (T-ALL), Burkitt lymphoma, and AIDS-related NHL (Brimmell et al., 1998; Inoue et al., 2000; Meijerink et al., 1998) . Two general types of BAX gene mutation have been reported ± frame-shift and missense. Frame-shift mutations arise due to alterations in a homopolymerics stretch of eight guanosine residues in the coding region of the BAX gene, where deletion (G 7 ) or addition (G 9 ) of a nucleotide throws-o the reading frame and prevents production of Bax protein. Mutations in nucleotide repeats are common in tumors with microsatellite instability (MSI), a molecular disorder caused by defects in proteins involved in DNA mismatch repair (reviewed in Perucho, 1996) . In a study of lymphoma and leukemia cell lines with the MSI phenotype, 82% (14/17) had frame-shift mutations in BAX involving the G 8 sequence (Inoue et al., 2000) .
Furthermore, BAX mutations were the most common lesion detected among all genes examined which are known to contain homopolymeric stretch of nucleotides in coding regions, including hMSH3, hMSH6, TGFbetaRII, and IGFIIR (Inoue et al., 2000) . This observation implies a strong selection for neoplastic clones in which one or both copies of the BAX gene have been inactivated. Missense mutations seen in the BAX gene can aect a variety of regions in the Bax protein, and some of them have been demonstrated by gene transfer experiments to impair Bax function (Gil et al., 1999) . Sometimes a single tumor will contain a frame-shift mutation in one allele of BAX and a missense mutation in the other (Simms et al., 1998) .
Though mutations inactivating the BAX gene may be relatively rare, reduced levels of Bax protein are commonly found in hematopoietic malignancies. Moreover, reduced levels of Bax or altered ratios of Bax: Bcl-2 may be of prognostic signi®cance in several types of leukemia. For instance, higher Bcl-2:Bax ratios have been associated with progression of CLL, shorter remission duration, and shorter survival (McConkey et al., 1996; Pepper et al., 1996 Pepper et al., , 1998a . Similarly, a study of patients with AML suggested that lower levels of Bax are associated with shorter survival (Ong et al., 2000) . Another study of AML patients failed to demonstrate prognostic signi®cance for Bax but higher Bcl-2:Bax ratios were associated with shorter survival (Kornblau et al., 2000) . The mechanisms responsible for reduced steady-state levels of Bax protein in leukemias are largely unknown at present.
C-IAP2
Chromosomal translocations involving the C-IAP2 gene at 11q21 have been observed in some MucosaAssociated Lymphomas of extranodal Tissues (MALTomas) (Morgan et al., 1999; Motegi et al., 2000; Uren et al., 2000) (Table 2) . These low-grade B-cell lymphomas produce structurally altered cIAP2 proteins, which fuse portions of the cIAP2 protein to segments of the protein encoded by the MALT1 (MLT1) locus at 18q21. The cIAP2 protein consists of three tandem BIR domains, followed by a CARD and then a RING zinc-®nger domain (reviewed in Deveraux and . The BIR domain is a zincbinding fold implicated in Caspase inhibition. The BIR-containing regions of some IAP-family proteins, including cIAP2, bind directly to Caspases and suppress their protease activity Roy et al., 1997) . In the couple of t(11;18) translocations molecularly analysed thus far, the predicted fusion protein that results fuses the three BIR domains of cIAP with the C-terminal portion of the protein encoded by the MALT1 gene. The resulting protein thus lacks the RING domain normally present in cIAP2. The signi®cance of this may be in part related to observations that IAP-family proteins lacking their C-terminal RING domains sometimes display enhanced anti-apoptotic functions (reviewed in Hay, 2000) . The RING domains of some IAPs bind Ubiquitin-conjugating enzymes (UBCs [E2s]), promoting Ubiquitination and proteasome-dependent degradation of IAP proteins (Yang et al., 2000) . Thus, dissociation of the RING from cIAP2 may promote accumulation of this protein in cells bearing the t(11:18). However, there is more to this story of C-IAP2-MALT1 gene fusion. The MALT1 locus encodes a para-Caspase, a putative protease structurally related to the Caspases (Uren et al., 2000) . Para-Caspase contains an N-terminal prodomain region consisting of a Death Domain (DD) and two Immunoglobulin (Ig) repeat domains, followed by the C-terminal domain which is predicted to adopt the same protein fold as the catalytic domain of Caspases. The MALT lymphoma t(11;18)(q21;q21) translocations eectively replace the prodomain or at least portions of the prodomain of the human para-Caspase with the three BIRs of c-IAP2. The function of para-Caspase is unknown, at present, but links to a pathway controlling NF-kB activation have begun to emerge (Uren et al., 2000) . In this regard, gene transfection studies indicate cIAP2-MALT1 fusion proteins are potent inducers of NF-kB, a transcription factor implicated in induction of anti-apoptotic genes, which is discussed in detail below. In contrast, expression of either the cIAP2 or MALT1 segments of these proteins separately failed to produce signi®cant NF-kB induction (Uren et al., 2000) . Thus, the cIAP2-MALT1 fusion proteins produced by t(11;18) translocations are endowed with a gain-of-function phenotype where NF-kB induction is concerned.
FAS (APO1; CD95)
Fas is a member of the TNF family of cytokine receptors, and a potent inducer of apoptosis (Locksley et al., 2001) . Fas plays a critical role in immune system homeostasis, eradicating potentially autoreactive lymphocytes and down-regulating immune responses after elimination of foreign antigen by reducing the numbers of expanded clones of antigen-speci®c T-cells and Bcells in peripheral lymphoid organs (reviewed in Krammer, 2000; Locksley et al., 2001; Nagata, 1997) . Germline mutations in Fas and Fas-Ligand have been discovered as the underlying basis for the lymphoproliferative autoimmune phenotype of lpr/lpr and gdl/gdl strain mice, respectively (Takahashi et al., 1994; Watanabe-Fukunaga et al., 1992) . Thus, the Fas/FasL system plays a critical role in lymphocyte homeostasis in vivo. FasL is also a principal weapon used by cytolytic T-cells for inducing apoptosis of virusinfected, tumorigenic, and allogenic cells (reviewed in Krammer, 2000) .
The cytosolic domain of Fas contains the Death Domain (DD) structure, which links it to the adapter protein FADD and (in turn) to pro-Caspases-8 and 10 (reviewed in Ashkenazi and Dixit, 1998; Cryns and Yuan, 1999) . Germline mutations in the human FAS gene are associated with autoimmune lymphoproliferative syndrome (ALPS), where mutant Fas proteins are produced (often containing missense or nonsense mutations within in the DD) (Fisher et al., 1995) . At least some of these mutant Fas proteins found in humans with ALPS have been shown to operate as trans-dominant inhibitors of wild-type Fas, probably explaining the dominant inheritance pattern of this disorder. In contrast, mutations in the fas gene of lprstrain mice produce a similar autoimmune lymphoproliferative disorder with a recessive inheritance pattern (Watanabe-Fukunaga et al., 1992) . FasL, like most TNF family members, is a trimer, and the receptor probably also forms trimers and perhaps higher-order oligomers, thus explaining why some Fas mutants could display dominant-negative eects on wild-type Fas while others might not. Indeed, mutant versions of Fas from some patients with hereditary ALPS have been demonstrated to antagonize wild-type Fas (Fisher et al., 1995) , probably forming mixed oligomers of wild-type and mutant molecules.
Somatic mutations in the FAS gene have been found in multiple myelomas (MMs) and non-Hodgkin's lymphomas (Gronbaek et al., 1998) . The frequency of FAS gene point mutation in MM appears to be approximately 10% (Landowski et al., 1997) . In a study of 150 cases of non-Hodgkin's lymphomas (NHLs) where the coding regions of the gene were systematically sequenced, FAS gene mutations were found in 16 (11%) of the tumors (Gronbaek et al., 1998) . Missense mutations within the death domain of the receptor were associated with retention of the wildtype allele, suggesting a dominant-negative mechanism, whereas missense mutations outside the death domain were associated with allelic loss. In this same study, FAS gene mutations were identi®ed in three (60%) of MALT-type lymphomas, nine (21%) diuse large Bcell lymphomas, two (6%) follicular center B-cell lymphomas, one (50%) anaplastic large cell lymphoma, and one unusual case of B-cell chronic lymphocytic leukemia (B-CLL) with a marked tropism for skin. Thus, FAS gene mutations occur in a broad range of lymphoma-types. Interestingly, among the 16 patients with somatic Fas mutations, 15 showed extranodal disease at presentation, and six relapsed in extranodal areas (Gronbaek et al., 1998) .
Fas expression confers important prognostic information for some patients with leukemia. The FAS gene encodes two protein isoforms through alternative mRNA splicing: full-length Fas which has a transmembrane domain and a soluble form of Fas that lacks this transmembrane domain (Cheng et al., 1994) . Full length Fas is the initiator of the receptor-mediated pathway of apoptosis. In contrast, soluble Fas is secreted into the extracellular environment where it acts as a decoy and binds Fas-ligand. As such, soluble Fas is an inhibitor of apoptosis. In a study of 59 patients with adult T-cell leukemia, levels of fulllength Fas expression did not correlate with patient survival. However, increased serum levels of soluble Fas were associated with reduced survival and remained an important predictor in multivariate analysis even after accounting for other clinical risk factors (Kamihira et al., 1999) . Higher levels of soluble Fas in serum have also been correlated with disease progression, advanced clinical stage and shorter survival in B-CLL and aggressive non-Hodgkin's lymphomas (Niitsu et al., 1999; Osorio et al., 2001 ).
CASPASE-10
Though less common than FAS gene mutations, germline mutations in the gene encoding pro-Caspase-10 have been identi®ed in some patient with ALPS . Caspases-8 and -10 contain two tandem copies of the Death Eector Domain (DED) and can be recruited to Fas and other TNF-family death receptor complexes through interactions with Fadd. Though somatic mutations in the genes encoding either pro-Caspase-8 or Caspase-10 have yet to be described in hematopoietic malignancies, in some types of solid tumors such as neuroblastoma, missense mutations in the CASPASE-8 gene have been documented, as well as gene silencing in association with hyper-methylation of CpG islands (Teitz et al., 2000) .
Upstream inputs into the apoptosis machinery
In addition to genes that encode core components of the apoptosis machinery, structural alterations have been identi®ed in genes that provide important regulatory inputs into the expression of apoptosis genes or the regulation of their encoded proteins. Some of the more prominent players are described here.
NF-kB
Alterations in genes encoding various modulators of NF-kB can occur in several types of B-cell malignancies, including NHLs, B-CLL, and MMs (Rayet and Gelinas, 1999) . NF-kB represents a family of transcription factors, comprising the REL gene family. NF-kB directly binds the promoters and induces expression of several anti-apoptotic genes, including the BCL-2 family members BCL-X and BFL-1, the IAP-family member C-IAP2, and the DED-family gene C-FLIP Micheau et al., 2001; Stroka et al., 1999; Wang et al., 1998a) . Thus, elevations in NF-kB activity can increase cellular resistance to apoptosis, aecting (a) the Intrinsic (mitochondrial) pathway through elevations in anti-apoptotic Bcl-2 family proteins, (b) the Extrinsic (TNF-family death receptor) pathway through upregulation of c-Flip, and (c) downstream common pathways involving eector Caspases, as a result of over-production of cIAP2. Recent data demonstrating pathological elevations in expression of the NF-kB target gene TRAF1 in NHLs and B-CLLs suggest that NF-kB activity may be high in at least half of all B-cell malignancies (Zapata et al., 2000) .
The ®rst example of NF-kB involvement in malignancy was provided by studies of the avian Rev-T retrovirus, a transforming retrovirus which causes rapidly fatal lymphomas in young chickens and which carries the v-Rel oncogene. The cellular homologue of this viral oncogene is C-REL, which encodes the p65 subunit of NF-kB. The classical form of NF-kB consists of a heterodimer of p50 and p65 subunits, where both subunits participate in binding characteristic DNA sequences in gene targets. The p65 subunit uniquely carries the trans-activation domain needed for coupling to host cell transcriptional machinery (reviewed in Silverman and Maniatis, 2001 ). Ampli®ca-tion of the C-REL gene has been reported in NHLs, occurring in *23% of diuse large B-cell lymphomas and commonly associated with extranodal presentation (Houldsworth et al., 1996) . Interestingly, p65 c-Rel contains Caspase cleavage sites that can inactive this transcription factor upon proteolysis, whereas v-Rel is lacking the sequence motifs recognized by these proteases (Barkett et al., 2001) . Moreover, somatic point mutations that decrease Caspase cleavability of cRel have been observed in NHLs (Gilmore, 1999) . The functional signi®cance of loss of Caspase cleavage sites in Rel oncoproteins however has been called into question, based on gene transfection comparisons of Caspase-sensitive and Caspase-resistant forms of c-Rel and v-Rel, which failed to document a dierence in transforming activity or transcriptional potency (Barkett et al., 2001) .
Other genetic alterations associated with dysregulation of NF-kB include somatic missense mutations in IkB in HD (Cabannes et al., 1999; Emmerich et al., 1999) and chromosomal translocations involving the IkB family member BCL-3 in B-CLL (Karnolsky, 2000) . IkB family proteins bind and sequester NF-kB complexes, preventing the transcription factor from entering the nucleus. Typically, IkB is regulated by ubiquitin-mediated turnover by the 26S proteasome. Mutations in IkB thus may enhance NF-kB activity either by producing unstable proteins or reducing the anity of IkB for NF-kB.
The BCL10 gene becomes activated in MALTomas as a result of t(1:14) translocations . Non-sense mutations that produce truncated Bcl-10 proteins have also been reported in lymphomas and other malignancies, though controversy exists about the frequency of such mutations (Gill et al., 1999; Liu et al., 2000) . BCL-10 encodes a CARD-carrying protein, which has been implicated in both apoptosis and NF-kB induction. The CARD of Bcl-10 binds a variety of other CARD-family proteins including Cardiak (Rip2; Rick), which in turn binds IKKg, a subunit of the IkB Kinase (IKK) complex. IKK contains two serine/threonine protein kinases IKKa and IKKb, which are supported by the scaold protein IKKg (Nemo). Over-expression of Bcl-10 or even just the CARD of Bcl-10 induces increases in NF-kB activity . In contrast, the non-CARD region of this protein may play a role in inducing apoptosis, possibly through indirect associations with pro-Caspase-9 (Yan et al., 1999) . Truncated versions of Bcl-10 lacking the C-terminal non-CARD domain display increased transforming activity in gene transfer experiments . Gene ablation studies in mice indicate an essential role for Bcl-10 in the induction of NF-kB by T-cell and B-cell antigen receptors but not by TNFa-or IL-1/Toll family receptors (Ruland et al., 2001) . Thus, it is perhaps not surprising that some lymphomas develop BCL-10 mutations during their pathogenesis or progression. Interestingly, Bcl-10 also binds para-Caspase, the product of the MALT1 (MLT1) locus (Uren et al., 2000) . Since translocations involving BCL-10 and MALT1 have been discovered in MALTomas, this ®nding raises the possibility that the interaction of these proteins is physiologically important, warranting further investigation. In particular, it would be interesting to explore whether para-Caspase participates in the proteolytic processing of p100 and p105 members of the NF-kB family, which are converted to p50 and p52 subunits of NF-kB by removal of regions containing ankyrin-domains (Belich et al., 1999; Xiao et al., 2001) .
AKT
The protein kinase Akt (PKB) plays important roles in linking growth factor receptors and oncoproteins to apoptosis pathways. The murine gene encoding Akt was ®rst discovered by virtue of its similarity to the vakt oncogene found in a transforming murine retrovirus recovered from a thymoma (Ahmed et al., 1993) .
Humans contain three AKT genes, AKT1, AKT2, and AKT3. Akt proteins can phosphorylate multiple proteins within the core apoptosis machinery. For example, the pro-apoptotic Bcl-2 family member BAD is a target of Akt. Phosphorylation of BAD by Akt inhibits its ability to heterodimerize with Bcl-X L , and promotes association of BAD with 14-3-3, which sequesters phospho-BAD in the cytosol (reviewed in Datta et al., 1999) . Akt also can phosphorylate human Caspase-9, blocking apoptosis down-stream of mitochondria (Cardone et al., 1998) . Another substrate of Akt which is relevant to apoptosis is Forkhead Transcription Factors (FKHD). Some FKHD family members appear to control apoptosis, perhaps by aecting transcription of the gene encoding FasL. Phosphorylation of FKHD by Akt results in its association with cytosolic 14-3-3, preventing nuclear entry . Akt may also play a role in NF-kB activation (Ozes et al., 1999) . Moreover, Akt has been implicated in suppression of Nur77 (TR3), an orphan member of the retinoid/steroid family of transcription factors (Pekarsky et al., 2001 ). Nur77 appears to play a critical role in apoptosis induced via the T-cell antigen receptor (TCR) complex in thymocytes, based on gene ablation studies in mice (Masuyama et al., 2001) .
In recent years, evidence of hyper-activity of kinase Akt has been found for many types of human cancers (reviewed in Stambolic et al., 1999) . The Akt protein contains a PH domain which binds phospholipid second messengers produced by Phosphatidylinositol 3' Kinase (PI3K). Elevations in the levels of these lipid second messengers result in recruitment of Akt to the plasma membrane, where it becomes activated by phosphorylation (reviewed in Datta et al., 1999) . These phospho-lipid second messangers are destroyed by PTEN, a lipid phosphatase and important tumor suppressor gene. Deletions and somatic point mutations that inactivative PTEN occur commonly in cancers, including NHLs (large B-cell lymphoma and anaplastic large cell lymphoma as well as Burkitt's lymphoma and lymphoblastic leukemia/lymphoma) and MMs (Sakai et al., 1998) . In MM cell lines, reexpression of PTEN abolishes tumorigenicity in mice (Ge and Rudiko, 2000) . Transgenic mice overexpressing an active form of PI3K in their T-cells develop a lymphoproliferative disorder and display increased propensity to develop thymic lymphomas (Borlado et al., 2000) .
In addition to PTEN loss, elevations in Akt activity can be achieved by activation of the TCL-1 gene. TCL-1 proto-oncogene on chromosome 14q32.1 is involved in chromosomal translocations (t(14;14) (q11;q32.1) and t(7;14) (q35;q32.1)) and inversions (inv14(q11;q32.1)) with the TCR a/D and TCR-b loci in T-cell leukemias, including some T-prolymphocytic leukemias (T-PLL), and T-acute and -chronic leukemias (Fu et al., 1994) . The TCL-1 gene product binds Akt, and may permit its activation in the absence of phospho-lipid second messengers or stabilize the active conformation of the kinase (Pekarsky et al., 2000) . The Tcl-1 protein also seems to play a role in regulating nuclear translocation of Akt, which presumably in¯uences its ability to interact with nuclear substrates such as Nur77 (TR3).
Though more indirect in its interactions with Akt, the product of the NPM/ALK oncogene found in many anaplastic lymphomas is also an Akt activator. More than half of all Anaplastic Lymphomas develop t(2;5) translocations, causing fusion of portions of the NPM and ALK gene loci (Ergin et al., 2001) . The *75 kDa fusion protein product of t(2;5) translocations joins the NH 2 -terminal portion of the Nucleolar Phosphoprotein Nucleophosmin (NPM) protein with the entire cytoplasmic portion of the receptor tyrosine kinase, known as Anaplastic Lymphoma Kinase (ALK). NPM/ALK encodes a constitutively activated tyrosine kinase, which activates phosphatidylinositol 3-kinase (PI3K) and its downstream eector, Akt (Slupianek et al., 2001) . PI3K forms complexes with the NPM/ALK fusion protein, and both PI3K and Akt kinase were demonstrated to be permanently activated in NPM/ ALK-transfected BaF3 murine hematopoietic cells and in NPM/ALK-positive, but not in NPM/ALK-negative, patient-derived anaplastic large cell lymphoma cell lines (Slupianek et al., 2001) . In addition, Akt is phosphorylated (activated) in clinical specimens isolated from the tumors of patients diagnosed with ALK-positive T/null-cell lymphomas (Slupianek et al., 2001) . The PI3K inhibitors wortmannin and LY294002 have been reported to induce apoptosis in NPM/ ALK+ cells in vitro, demonstrating the functional importance of this pathway connecting NPM/ALK to PI3K (Bai et al., 2000) . Furthermore, dominantnegative mutants of either PI3K or Akt can inhibit proliferation and clonogenic expansion in vitro of cells expressing the NPM/ALK oncoprotein, while Akt dominant-negative suppressed the tumorigenicity of NPM/ALK-expressing lymphoid cells in mice. Thus, NPM/ALK constitutively activates the PI3K-Akt pathway and this pathway plays an important role in the NPM/ALK-mediated malignant transformation. (Bai et al., 2000; Slupianek et al., 2001) .
The BCR-ABL oncogene of Chronic Myelogenous Leukemia also is relevant to mechanisms of Akt activation. The BCR-ABL fusion protein is created as a result t(9;22) translocations. This fusion protein is pathognomonic for CML and is found in 25% of adult ALLs, where it confers a poor prognosis (Radich, 2001) . This fusion protein dysregulates the ABL tyrosine kinase leading to activation of several signaling pathways including Ras, AKT/P13Kinase, NF-kB and STAT. The BCR-ABL fusion protein inhibits apoptosis, in part, by constitutively activating STAT 5, an activator of BCL-X gene transcription (Wang, 2000) .
P53
The tumor suppressor p53 is a transcription factor, which is capable of inducing apoptosis. Multiple apoptosis-relevant targets of p53 have been described in the past several years. The ®rst pro-apoptotic gene found to be directly induced by p53 was BAX (Miyashita and Reed, 1995) . Several copies of p53 binding sites have been identi®ed in the promoter of the human BAX gene. Interestingly, however, BAX gene induction by p53 appears to be in¯uenced by other unidenti®ed factors, possibly having to do with the ratio of p53 to its close cousins p63 and p73 or perhaps related to whether other transcription factors also occupy the BAX promoter simultaneously with p53. Since the discovery that p53 regulates BAX expression, several additional direct targets of p53 have been found which constitute core-components of the apoptosis machinery, including the Bcl-2 family members PUMA and APR (noxa) and the TNF-family death receptors FAS and DR5 (Nakano and Vousden, 2001; Oda et al., 2000; Owen-Schaub et al., 1995; Wu et al., 1997; Yu et al., 2001) . The relative importance of each of these p53 target genes for p53-mediated apoptosis probably is highly dependent on cellular and environmental context. Though p53 is also involved in cell cycle arrest, DNA-repair, and other processes, the importance of its apoptosis-inducing activity for tumor suppression has been documented in vivo using genetically engineered mice (Yin et al., 1997) .
Deletion and inactivating mutations of the p53 gene at 17p13.1 are common in human cancers, and hematopoietic malignancies are no exception (Table  2) . Many NHLs and AMLs, for example, suer loss of function mutations in p53 at some point during their progression to lethal disease. However, indirect mechanisms for thwarting the actions of p53 have also been uncovered, and some of these can also be relevant to neoplasms of hematopoietic and lymphoid origin. For example, for p53 to become active as a transcription factor, it must undergo phosphorylation at key residues. Among the more important kinases involved in p53 phosphorylation and activation is ATM. Hereditary mutations in the ATM gene were ®rst associated with ataxia telangiectasia, a syndrome characterized by defective DNA repair and a high incidence of T-cell neoplasms (reviewed in Lengauer et al., 1998) . In B-CLL, it is estimated that *30% of cases develop loss of heterozygosity (LOH) at the ATM locus on 11q22-23 (Kitada et al., 1998; Pettitt et al., 2001) , associated with progression to more aggressive disease. Typically, one allele of ATM is deleted and the other is inactivated by single nucleotide alterations that create missense mutations. ATM mutations and LOH are also common events in T-PLL and mantel cell lymphomas (MCLs) (Boultwood, 2001; Soulier et al., 2001; Stamkovic et al., 2001; Yuille et al., 1998) .
Several other mechanisms of interfering with p53 function have been described in human cancers (Vogelstein et al., 2000) . The Mdm2 protein binds p53 and targets it for ubiquitination and proteasomedependent degradation, thus keeping p53 protein levels low (reviewed in Prives, 1998) . MDM2 gene ampli®ca-tion at 12q13-14 has been detected in 11 ± 23% of diuse large B-cell lymphomas, typically associated with advanced stage disease (Rao et al., 1998) . Ampli®cation of the MDM2 gene locus has also been described in Hodgkin's disease (Kupper et al., 2001) . MDM2 is over-expressed in some B-CLLs. Though gene ampli®cation has not been described, trisomy 12 is a common genetic abnormality in B-CLL, often associated with more aggressive disease (Huang et al., 1994) . In addition to Mdm2, chromosomal translocations involving the MLL (mixed lineage leukemia) gene on 11q23 are found in 4% of AMLs and may be relevant to p53 in some cases, particularly in the case of the t(11;19) translocations that fuse MLL with the ELL (MEN) gene (Grimwade et al., 1998) . Dysregulated ELL gene expression inhibits apoptosis by binding p53 and reducing its transcriptional activity (Shinobu et al., 1999) . Also, CBFb (SMMHC) is overexpressed in a AMLs harboring the inversion 16 chromosomal abnormality. An increase in this gene product can lead to down-regulation of p53 and subsequent chemoresistance in AML cell lines (BritosBray et al., 1998) (Table 2) .
PML
The t(15;17) translocation results in fusion of portions of the PML and retinoic acid receptor (RARa) genes, and production of PML-RARa fusion proteins (Kakizuka et al., 1991) . This translocation is found in most acute promyelomonocytic leukemias (APML) (Fabclass, M3). Though early attention focused on RAR, more recently PML has emerged as an interesting protein in its own right. PML is normally localized to subregions of the nucleus called PML Oncogenic Domains (PODs) or Nuclear Bodies (NBs). Targeting of PML to these structures is dependent on covalent attachment of SUMO, a ubiquitin-like protein (Muller et al., 1998) . Data from pml 7/7 knock-out mice indicate that loss of this protein is associated with a generalized apoptosis-resistant state (Wang et al., 1998b) . PML binds Daxx, another protein implicated in apoptosis regulation, whose mechanism remains controversial (Zhong et al., 2000) . Daxx over-expression enhances apoptosis, particularly apoptosis induced via TNF-family death receptors and the Extrinsic pathway, while dominantnegative fragments of Daxx have the opposite eect (Torii et al., 1999) .
The PML-RARa fusion proteins found in APMLs fail to localize properly to PODs, thus interfering with PML function. However, stimulation of RARa with retinoids results in targeting of the PML-RARa protein to PODs, and restores apoptosis sensitivity (Dyck et al., 1994) . Conversely, over-expression of PML-RARa fusion transcription in leukemia cell lines inhibits apoptosis (Grignani et al., 1993) , possibly because PML-RARa binds endogenous PML and interferes with its targeting to PODs. At present, it remains unclear how PML regulates apoptosis, but in¯uencing transcription of apoptosis-relevant genes is among the leading candidate mechanisms (reviewed in Melnick and Licht, 1999) .
Other genetic changes
The foregoing discussion of NF-kB, Akt, p53, and PML illustrates how genetic alteration of genes that provide upstream inputs into the core apoptosis machinery can deregulate apoptosis mechanisms in hematopoietic malignancies. Multiple additional examples of indirect mechanisms for altering apoptosis pathways probably exist, awaiting further investigations of the molecular events that link them to apoptosis-regulating proteins. Among these are members of the basic helix ± loop ± helix (bHLH) family of transcription factors, such as EA2, which are frequently involved in chromosomal translocations in the human leukemias and which share sequence similarity to proteins involved in cell death regulation in lower organisms (reviewed in Look, 1997).
Therapeutic opportunities from apoptosis targets
Emerging knowledge about the proteins that constitute the apoptosis core machinery and their upstream inputs has revealed multiple new opportunities for therapeutic intervention, some of which are already under investigation in clinical trials. With respect to core apoptosis targets, for example, nuclease-resistant (phosphothioate) antisense oligonucleotides directed against BCL-2 mRNA are currently in Phase III trials for patients with MM, and in Phase II for NHL, B-CLL, and AML (http://genta.com). Small-molecule compounds that mimic the BH3 domains of proapoptotic proteins have also been described (Degterev et al., 2001; Tzung et al., 2001; Wang et al., 2000) , suggesting additional opportunities for interfering with Bcl-2 using more traditional approaches. A path to IAP antagonists has been revealed by structural analysis of BIR domains of IAPs in complexes with the endogenous IAP-inhibitor SMAC. Only the ®rst four amino-acids of the mature SMAC protein binds BIR3 of XIAP at a site required for Caspase-9 interaction (Chai et al., 2000) , raising hopes that non-peptidyl mimetics of this tetramer sequence could be generated. Recombinant TRAIL protein (extracellular domain) has been produced and shown to display promising anti-tumor activity in tumor xenograft studies in mice . Unlike previously tested TNF-family members, TRAIL exhibits little toxicity towards normal tissues, possibly because normal cells may express an abundance of neutralizing decoy receptors for this ligand and/or because they may express less of the DR5 death receptor (Ashkenazi and Dixit, 1999) . Clinical trials of TRAIL are slated to begin shortly. Of interest for hematopoietic malignancies, it was recently shown that the retinoid, all-trans retinoic acid (ATRA), induces apoptosis in PML-RARa-expressing APML cells through induction and autocrine/paracrine action of TRAIL (Altucci et al., 2001) . Furthermore, the addition of exogenous TRAIL to APL cells and an ATRA-resistant cell line induced apoptosis. Therefore, TRAIL may have a role in the treatment of APL, perhaps in synergy with ATRA. TRAIL may also be quite useful in treating patients with ATRA-resistant disease. Though most hematopoietic malignancies are not intrinsically sensitive to TRAIL (Snell et al., 1997; Wuchter et al., 2001) , additional approaches to sensitizing malignant cells to TRAIL have begun to emerge, such as using PPARg modulatory drugs that seem to reduce levels of the Caspase-8 antagonist cFlip (Goke et al., 2000; Kim et al., submitted) .
Regarding upstream inputs into core apoptosis machinery, small molecule inhibitors of the IkB kinases have been identi®ed (Holmes-McNary and Baldwin, 2000; Rossi et al., 2000; Suh et al., 1999) , raising hopes of suppressing NF-kB in neoplastic cells. At least two structural classes of compounds that inhibit the 26S proteasome are currently in clinical trials (reviewed in Adams et al., 2000) . Though proteasome inhibitors aect many cellular processes, prevention of IkB degradation probably makes contributions to the apoptosis induction frequently observed. Small molecule inhibitors of Akt have yet to be reported, but upstream of Akt, a compound that inhibits the kinase activity of BCR/ABL (STI-571 [Gleevac r ]) has recently been approved, providing a powerful weapon in the armamentarium of agents for combating this form of leukemia. This compound induces apoptosis in leukemic cells over-expressing BCR-ABL and has signi®cant clinical bene®t in patients with CML (Druker et al., 2001b) and BCR-ABL positive ALL (Druker et al., 2001a) .
Other agents that have recently been identi®ed with unique apoptosis-inducing mechanisms include triterpenoids, such as 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO). CDDO is a weak PPARg agonist, and weak IKK inhibitor that induces apoptosis in leukemic cell lines by activating pro-Caspase-8 (Ito et al., 2000) . Though the relevant mechanisms remain to be elucidated, agents which trigger the Extrinsic pathway (death receptor/caspase-8) are particularly intriguing, since nearly all anti-cancer drugs utilize the Intrinsic pathway (mitochondria/caspase-9) to induce apoptosis, and thus chemo-resistant cells often have defects in the Intrinsic pathway. Consistent with this notion, over-expression of Bcl-X L has little eect on apoptosis induction by CDDO in leukemia cell lines in vitro (Ito et al., 2000) . CDDO will soon be entering human clinical trials. Various retinoids or retinoid-like compounds have also been described which induce apoptosis of leukemia cells, probably at least in part by down-regulating expression of anti-apoptotic proteins of the Bcl-2 family. These agents include a RXRselective agonist, recently approved for cutaneous Tcell lymphomas and Sezary syndrome (http://ligandpharm.org), as well as 4-hydroxy-retinimide and AHPN (CD437) analogues (Li et al., 1998b; Reed, 1999b) . Histone Deacetylase (HDAC) inhibitors also can reduce transcription of anti-apoptotic Bcl-2 family proteins in cancers (Hague et al., 1997; Mandal and Kumar, 1996) , and are currently under investigation in clinical trials. Lastly, small molecule compounds have been described which can restore activity to at least some mutant forms of the p53 protein (Foster et al., 1999) . For the most part, unfortunately, these p53 reactivators are not generally applicable. However, in a novel twist on exploiting compounds that modulate apoptosis pathways, small molecule drugs have been revealed that block the activity of wild-type p53, and it has been proposed that these might be employed for ameliorating the toxic side-eects to normal tissue of chemotherapy in patients harboring p53-mutant/null tumors (Komarov et al., 1999) . Altogether therefore, prospects are bright for translation of concepts emerging from apoptosis research into more ecacious therapies for the treatment of malignancies of hematopoietic and lymphoid origin.
